Stocklytics Platform
Asset logo for symbol QNCX
Cortexyme
QNCX56
$1.96arrow_drop_down5.28%-$0.11
Penny Stock
Asset logo for symbol QNCX
QNCX56

$1.96

arrow_drop_down5.28%

Performance History

Chart placeholder
Key Stats
Open$1.85
Prev. Close$1.84
EPS-1.26
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$91.52M
PE Ratio-
LOWHIGH
Day Range1.79
2.12
52 Week Range0.51
2.12
Ratios
Revenue-
EBITDA Margin %-
EPS-1.26

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Cortexyme (QNCX)

Quince Therapeutics, Inc. (QNCX) is a biopharmaceutical company focused on developing innovative therapies for the treatment of various diseases. The company's primary goal is to harness the power of gene therapy and advanced drug delivery technologies to create novel treatments that can provide long-lasting benefits to patients. With a strong pipeline of promising candidates, Quince Therapeutics is well-positioned for future growth and success. The company's stock price history has shown steady growth over the years, reflecting investor confidence in its potential. Investors can stay updated on the latest developments and news related to Quince Therapeutics by checking out the company's quote and stock news.
When it comes to stock analysis, Quince Therapeutics, Inc. (QNCX) has a lot to offer. With a team of experienced analysts and advanced analytical tools, the company provides comprehensive insights into the performance and potential of its stock. Investors can benefit from the smart analysis provided by Quince Therapeutics to make informed investment decisions. The company's market cap is an important factor to consider, as it reflects the overall value of the company's outstanding shares. The PEG ratio is another useful metric that can help investors evaluate the stock's potential relative to its earnings growth.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Dirk Thye M.D.
Headquarters
South San Francisco
Employees
21
Exchange
NASDAQ
add Cortexyme  to watchlist

Keep an eye on Cortexyme

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the market capitalization of Cortexyme (QNCX)?

Cortexyme (QNCX) has a market capitalization of $96.8M. The average daily trading volume is 2.13, indicating the stock's liquidity and investor engagement.
help

What is Cortexyme 's (QNCX) price per share?

The current price per share for Cortexyme (QNCX) is $1.96. The stock has seen a price change of -$0.11 recently, indicating a -5.29% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Cortexyme (QNCX)?

For Cortexyme (QNCX), the 52-week high is $2.46, which is 25.26% from the current price. The 52-week low is $0.51, the current price is 282.81% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Cortexyme (QNCX) a growth stock?

Cortexyme (QNCX) has shown an average price growth of -6.03% over the past three years. It has received a score of 74 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cortexyme as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Cortexyme (QNCX) stock price performance year to date (YTD)?

As of the latest data, Cortexyme (QNCX) has a year-to-date price change of 88.46%. Over the past month, the stock has experienced a price change of 140.05%. Over the last three months, the change has been 206.25%. Over the past six months, the figure is 127.91%.
help

Is Cortexyme (QNCX) a profitable company?

Cortexyme (QNCX) has a net income of -$31.38M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$34.62M. Furthermore, the EBITDA is -$29.13M.

Take Your Investments to a Whole New Level